CD133 suppresses neuroblastoma cell differentiation via signal pathway modification

Oncogene

Volumn 30, Issue 1, 2011, Pages 97-105

  Takenobu, H ^a   Shimozato, O ^a   Nakamura, T ^b   Ochiai, H ^a,c   Yamaguchi, Y ^a   Ohira, M ^a   Nakagawara, A ^a   Kamijo, T ^a  

^a CHIBA CANCER CENTER   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

CD133; differentiation; neuroblastoma; PI3K Akt; RET p38MAPK

Indexed keywords

CD133 ANTIGEN; NEUROTROPHIC FACTOR; PROTEIN RET; REPRESSOR PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; ENZYME REGULATION; FEMALE; GENETIC TRANSCRIPTION; GLIA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NEURITE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; GLYCOPROTEINS; HEK293 CELLS; HUMANS; MICE; MICE, NUDE; NEUROBLASTOMA; PEPTIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-RET; SIGNAL TRANSDUCTION;

EID: 78650970554     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.383     Document Type: Article

References (42)

1. Aoyama M, Ozaki T, Inuzuka H, Tomotsune D, Hirato J, Okamoto Y et al. (2005). LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma. Cancer Res 65: 4587-4597.
2. Boivin D, Labbe D, Fontaine N, Lamy S, Beaulieu E, Gingras D et al. (2009). The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. Biochemistry 48: 3998-4007.
3. Brodeur GM, Sawada T, Tsuchida Y, Voute PA (eds) (2000). Neuroblastoma. Elsevier Science: Amsterdam.
4. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951.
5. Corbeil D, Roper K, Hellwig A, Tavian M, Miraglia S, Watt SM et al. (2000). The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 275: 5512-5520.
6. Corbeil D, Fargeas CA, Huttner WB. (2001). Rat prominin, like its mouse and human orthologues, is a pentaspan membrane glyco-protein. Biochem Biophys Res Commun 285: 939-944.
7. Crowder RJ, Enomoto H, Yang M, Johnson Jr EM, Milbrandt J. (2004). Dok-6, a Novel p62 Dok family member, promotes Ret-mediated neurite outgrowth. J Biol Chem 279: 42072-42081.
8. D'Alessio A, De Vita G, Cal? G, Nitsch L, Fusco A, Vecchio G et al. (1995). Expression of the RET oncogene induces differentiation of SK-N-BE neuroblastoma cells. Cell Growth Differ 6: 1387-1394.
9. Enomoto H, Crawford PA, Gorodinsky A, Heuckeroth RO, Johnson Jr EM, Milbrandt J. (2001). RET signaling is essential for migration, axonal growth and axon guidance of developing sympathetic neurons. Development 128: 3963-3974.
10. Enomoto H, Heuckeroth RO, Golden JP, Johnson EM, Milbrandt J. (2000). Development of cranial parasympathetic ganglia requires sequential actions of GDNF and neurturin. Development 127: 4877-4889.
11. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM et al. (2006). Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 66: 7445-7452.
12. Hansford LM, McKee AE, Zhang L, George RE, Gerstle JT, Thorner PS et al. (2007). Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res 67: 11234-11243.
13. Hasegawa K, Nakamura T, Harvey M, Ikeda Y, Oberg A, Figini M et al. (2006). The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res 12: 6170-6178.
14. Itoh F, Ishizaka Y, Tahira T, Yamamoto M, Miya A, Imai K et al. (1992). Identification and analysis of the ret proto-oncogene promoter region in neuroblastoma cell lines and medullary thyroid carcinomas from MEN2A patients. Oncogene 7: 1201-1206.
15. Iehara T, Hosoi H, Akazawa K, Matsumoto Y, Yamamoto K, Suita S et al. (2006). MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening. Br J Cancer 94: 1510-1515.
16. Jordan CT, Guzman ML, Noble M. (2006). Cancer stem cells. N Engl J Med 355: 1253-1261.
17. Kaplan D, Matsumoto K, Lucarelli E, Thiele CJ. (1993). Induction of TrkB by retinoic acid mediates biologic responsiveness to BDNF and differentiation of human neuroblastoma cells. Eukaryotic Signal Transduction Group. Neuron 11: 321-331.
18. Kaneko M, Tsuchida Y, Mugishima H, Ohnuma N, Yamamoto K, Kawa K et al. (2002). Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol 24: 613-621.
19. Klein R. (1994). Role of neurotrophins in mouse neuronal development. FASEB J 8: 738-744.
20. Kurata K, Yanagisawa R, Ohira M, Kitagawa M, Nakagawara A, Kamijo T. (2008). Stress via p53 pathway causes apoptosis by mitochondrial Noxa upregulation in doxorubicin-treated neuro-blastoma cells. Oncogene 27: 741-754.
21. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. (2007). CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27: 1749-1758.
22. Maris JM, Hogarty MD, Bagatell R, Cohn SL. (2007). Neuroblasto-ma. Lancet 369: 2106-2120.
23. Maw MA, Corbeil D, Koch J, Hellwig A, Wilson-Wheeler JC, Bridges RJ et al. (2000). A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. Hum Mol Genet 9: 27-34.
24. Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S et al. (2007). Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 67: 3153-3161.
25. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C et al. (2007). Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43: 935-946.
26. 0 splicing variants and polyadeny-lation sites: a novel C-terminus for RET. Oncogene 11: 2039-2045.
27. Nakanishi H, Ozaki T, Nakamura Y, Hashizume K, Iwanaka T, Nakagawara A. (2007). Purification of human primary neuroblas-tomas by magnetic beads and their in vitro culture. Oncol Rep 17: 1315-1320.
28. Nikolova T, Wu M, Brumbarov K, Alt R, Opitz H, Boheler KR et al. (2007). WNT-conditioned media differentially affect the proliferation and differentiation of cord blood-derived CD133+ cells in vitro. Differentiation 75: 100-111.
29. O'Brien CA, Pollett A, Gallinger S, Dick JE. (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
30. Ochiai H, Takenobu H, Nakagawa A, Yamaguchi Y, Kimura M, Ohira M et al. (2010). Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bb and TSLC1 in neuroblastoma. Oncogene 29: 2681-2690.
31. Ohira M, Morohashi A, Inuzuka H, Shishikura T, Kawamoto T, Kageyama H et al. (2003). Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets. Oncogene 22: 5525-5536.
32. Olempska M, Eisenach PA, Ammerpohl O, Ungefroren H, Fandrich F, Kalthoff H. (2007). Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 6: 92-97.
33. Peterson S, Bogenmann E. (2004). The RET and TRKA pathways collaborate to regulate neuroblastoma differentiation. Oncogene 23: 213-225.
34. Reya T, Morrison SJ, Clarke MF, Weissman IL. (2001). Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
35. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C et al. (2007). Identification and expansion of human colon-cancer initiating cells. Nature 445: 111-115.
36. Shmelkov SV, Jun L, St Clair R, McGarrigle D, Derderian CA, Usenko JK et al. (2004). Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 103: 2055-2061.
37. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. (2004). Identification of human brain tumour initiating cells. Nature 432: 396-401.
38. Walton JD, Kattan DR, Thomas SK, Spengler BA, Guo HF, Biedler JL et al. (2004). Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia 6: 838-845.
39. Weinberg RA (ed) (2006). The Biology of Cancer. Garland Science: New York.
40. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG et al. (1997). AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012.
41. Yin S, Li J, Hu C, Chen X, Yao M, Yan M et al. (2007). CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120: 1444-1450.
42. Zacchigna S, Oh H, Wilsch-Brauninger M, Missol-Kolka E, Jaszai J, Jansen S et al. (2009). Loss of the cholesterol-binding protein prominin-1/CD133 causes disk dysmorphogenesis and photoreceptor degeneration. J Neurosci 29: 2297-2308.